# Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo

> **NCT00851344** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 54 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **DRUG:** GSK835726 (10mg)
- **DRUG:** GSK835726 (50mg)
- **DRUG:** GSK835726 (100mg)
- **DRUG:** Cetirizine (10mg)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00851344
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2016-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00851344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00851344, "Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00851344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*